NGG vs. GSK

Last updated Apr 1, 2026

Compare and contrast key facts about National Grid plc (NGG) and GlaxoSmithKline plc (GSK).

Performance

NGG vs. GSK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in National Grid plc (NGG) and GlaxoSmithKline plc (GSK). The values are adjusted to include any dividend payments, if applicable.

NGG vs. GSK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NGG National Grid plc	9.37%	35.88%	-1.26%	18.82%	-12.68%	29.02%	-0.75%	38.53%	-13.76%	4.94%
GSK GlaxoSmithKline plc	13.45%	51.23%	-5.14%	9.71%	-33.41%	26.74%	-17.72%	29.24%	13.79%	-2.97%

Fundamentals

Market Cap NGG : $83.75B GSK : $112.75B
EPS NGG : $4.66 GSK : $2.78
PE Ratio NGG : 18.17 GSK : 19.82
PEG Ratio NGG : 0.50 GSK : 1.33
PS Ratio NGG : 2.31 GSK : 3.54
PB Ratio NGG : 2.25 GSK : 6.90
Total Revenue (TTM) NGG : $36.25B GSK : $31.95B
Gross Profit (TTM) NGG : $9.82B GSK : $23.18B
EBITDA (TTM) NGG : $12.97B GSK : $11.62B

Returns By Period

In the year-to-date period, NGG achieves a 9.37% return, which is significantly lower than GSK's 13.45% return. Over the past 10 years, NGG has outperformed GSK with an annualized return of 7.77%, while GSK has yielded a comparatively lower 5.74% annualized return.

NGG

• 1D: 1.09%
• 1M: -9.78%
• YTD: 9.37%
• 6M: 18.08%
• 1Y: 34.59%
• 3Y*: 15.65%
• 5Y*: 14.22%
• 10Y*: 7.77%

GSK

• 1D: 1.77%
• 1M: -6.66%
• YTD: 13.45%
• 6M: 30.03%
• 1Y: 48.15%
• 3Y*: 20.43%
• 5Y*: 8.75%
• 10Y*: 5.74%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NGG vs. GSK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NGG

NGG Risk / Return Rank: 84
NGG Sharpe Ratio Rank: 86
NGG Sortino Ratio Rank: 79
NGG Omega Ratio Rank: 82
NGG Calmar Ratio Rank: 84
NGG Martin Ratio Rank: 88

GSK

GSK Risk / Return Rank: 85
GSK Sharpe Ratio Rank: 88
GSK Sortino Ratio Rank: 84
GSK Omega Ratio Rank: 81
GSK Calmar Ratio Rank: 88
GSK Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NGG vs. GSK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for National Grid plc (NGG) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NGG	GSK	Difference
Sharpe ratio Return per unit of total volatility	1.54	1.70	-0.16
Sortino ratio Return per unit of downside risk	2.01	2.30	-0.28
Omega ratio Gain probability vs. loss probability	1.29	1.29	0.00
Calmar ratio Return relative to maximum drawdown	2.71	3.25	-0.54
Martin ratio Return relative to average drawdown	8.94	7.56	+1.38
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NGG vs. GSK - Sharpe Ratio Comparison

The current NGG Sharpe Ratio is 1.54, which is comparable to the GSK Sharpe Ratio of 1.70. The chart below compares the historical Sharpe Ratios of NGG and GSK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NGG	GSK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.54	1.70	-0.16
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.66	0.36	+0.31
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.34	0.25	+0.09
Sharpe Ratio (All Time) Calculated using the full available price history	0.37	0.33	+0.04

Correlation

The correlation between NGG and GSK is 0.40, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

NGG vs. GSK - Dividend Comparison

NGG's dividend yield for the trailing twelve months is around 3.69%, more than GSK's 3.19% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NGG National Grid plc	3.69%	4.03%	11.81%	5.20%	5.18%	4.75%	5.32%	4.94%	6.51%	14.95%	5.07%	4.73%
GSK GlaxoSmithKline plc	3.19%	3.42%	4.60%	3.75%	5.47%	4.99%	5.59%	4.35%	5.65%	5.83%	6.86%	5.93%

Drawdowns

NGG vs. GSK - Drawdown Comparison

The maximum NGG drawdown since its inception was -54.85%, roughly equal to the maximum GSK drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for NGG and GSK.

Drawdown Indicators

	NGG	GSK	Difference
Max Drawdown Largest peak-to-trough decline	-54.85%	-55.70%	+0.85%
Max Drawdown (1Y) Largest decline over 1 year	-12.79%	-14.80%	+2.01%
Max Drawdown (5Y) Largest decline over 5 years	-39.20%	-50.10%	+10.90%
Max Drawdown (10Y) Largest decline over 10 years	-39.20%	-50.10%	+10.90%
Current Drawdown Current decline from peak	-9.93%	-9.07%	-0.86%
Average Drawdown Average peak-to-trough decline	-13.45%	-18.90%	+5.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.88%	6.37%	-2.49%

Volatility

NGG vs. GSK - Volatility Comparison

National Grid plc (NGG) has a higher volatility of 7.98% compared to GlaxoSmithKline plc (GSK) at 7.26%. This indicates that NGG's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NGG	GSK	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.98%	7.26%	+0.72%
Volatility (6M) Calculated over the trailing 6-month period	13.20%	19.71%	-6.51%
Volatility (1Y) Calculated over the trailing 1-year period	22.50%	28.43%	-5.93%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	21.50%	24.74%	-3.24%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	22.85%	22.72%	+0.13%

Financials

NGG vs. GSK - Profitability Comparison

The chart below illustrates the profitability comparison between National Grid plc and GlaxoSmithKline plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NGG - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, National Grid plc reported a gross profit of 1.61B and revenue of 7.05B. Therefore, the gross margin over that period was 22.9%.

GSK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported a gross profit of 5.49B and revenue of 7.90B. Therefore, the gross margin over that period was 69.5%.

NGG - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, National Grid plc reported an operating income of 1.61B and revenue of 7.05B, resulting in an operating margin of 22.9%.

GSK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported an operating income of 179.89M and revenue of 7.90B, resulting in an operating margin of 2.3%.

NGG - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, National Grid plc reported a net income of 615.54M and revenue of 7.05B, resulting in a net margin of 8.7%.

GSK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported a net income of 627.73M and revenue of 7.90B, resulting in a net margin of 7.9%.